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ABSTRACT
Objective: To assess the effect of catheter ablation on
atrial fibrillation (AF) symptoms and quality of life
(QoL).
Methods: Patients with AF scheduled for ablation
were recruited. Pulmonary vein isolation (PVI) was
performed and complex fractionated atrial electrogram
(CFAE)±linear ablation undertaken in patients in AF
despite PVI. QoL and AF symptoms were assessed
using SF-36 V2 and Atrial Fibrillation Effect on Quality-
of-Life (AFEQT) questionnaires before and 3 months
after ablation. Change in QoL scores after ablation was
correlated with clinical parameters and the extent of
ablation. Magnitude of QoL change was compared
between AFEQT and SF-36 physical component
summary (PCS) and mental component summary
(MCS) scores and correlated with arrhythmia outcome.
Results: 80 patients were studied. Summative and
individual health scores for both AFEQT (51.5±22.0 vs
81.3±18.2; p<0.01) and SF-36 (PCS 43.3±10.5 vs 47.9
±11.3; p<0.01 and MCS 45.0±11.5 vs 51.5±9.4;
p<0.01) improved significantly in patients who
maintained sinus rhythm after ablation, but not in
those with recurrent AF. Improvement in AFEQT (25.4
±19) was significantly greater than change in PCS (6.8
±6.4; p<0.01) and MCS (8.5±7.9; p<0.01) scores and
correlated more closely with arrhythmia outcome
(AFEQT r=0.55; PCS r=0.26; MCS r=0.30).
Conclusions: Patients who maintained sinus rhythm
after ablation had a significant improvement in AF
symptoms and QoL; however, no improvement was
observed in patients with recurrent AF. QoL change
after ablation did not correlate with baseline clinical
parameters or ablation strategy. AF specific QoL scales
are more responsive to change and correlate better
with ablation outcome.
INTRODUCTION
Atrial fibrillation is the most common
arrhythmia in clinical practice affecting up to
2% of the general population and is asso-
ciated with significant morbidity and mortal-
ity.1 Although some patients with AF are
asymptomatic, the majority seek treatment to
reduce symptoms and improve quality of life
(QoL), which is reduced compared to the
general population.2–4 Treatment strategies
including antiarrhythmic drugs,5 ventricular
rate control6 and catheter ablation7 improve
QoL particularly if sinus rhythm can be
restored and maintained.8 However, several
KEY QUESTIONS
What is already known about this subject?
▸ Previous research has shown that catheter abla-
tion improves symptoms and quality of life
(QoL) in patients with AF irrespective of arrhyth-
mia outcome and that this improvement is sus-
tained for several years.
What does this study add?
▸ Summative and individual health domain scores
for both Atrial Fibrillation Effect on Quality-of-
Life (AFEQT) (AF specific) and SF-36 V2
(generic) questionnaires improved significantly
in patients who maintained sinus rhythm after
ablation; however, there was no improvement in
patients with recurrent atrial fibrillation (AF).
▸ Magnitude of QoL change after ablation did not
correlate with clinical parameters (including AF
type) or ablation strategy.
▸ Change in AFEQT was significantly greater than
change in SF-36 scores and correlated more
closely with arrhythmia outcome following
ablation.
How might this impact on clinical practice?
▸ The similar degree of QoL improvement after
ablation in paroxysmal and persistent AF sup-
ports the continued use of catheter ablation in
both patient groups.
▸ AF specific QoL scales (eg, AFEQT) are more sen-
sitive to change after ablation and correlate better
with arrhythmia outcome. Therefore, studies
assessing QoL in patients with AF should use AF
specific rather than generic QoL scales.
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studies have reported an improvement in QoL after abla-
tion irrespective of procedural outcome.9–11 The most
widely validated generic QoL scale is the Medical
Outcomes Study Short Form Health Survey (SF-36),
which has been successfully used to study a range of car-
diovascular conditions including AF.12 The greatest weak-
ness of generic QoL measures is that, by design, they
reflect general health and functioning, and therefore,
results are strongly influenced by patient demographics
and comorbidity. Therefore, Spertus et al13 developed
the Atrial Fibrillation Effect on Quality-of-Life (AFEQT)
questionnaire as a disease-specific measure to evaluate
QoL in AF patients. The aim of this study was to assess
the effect of catheter ablation on AF symptoms and QoL
in patients with paroxysmal or persistent AF using the
AFEQT and SF-36 V2 questionnaires.
METHODS
Patient recruitment
Study participants were recruited from patients sched-
uled to undergo their first catheter ablation procedure
for symptomatic AF. In line with usual practice, class I
and III antiarrhythmic drugs were discontinued five half-
lives prior to ablation and only restarted in patients with
recurrent AF after ablation.
Ethical approval
This study complies with the Declaration of Helsinki and
was granted a favourable ethical opinion by the National
Research Ethics North West Committee (REC reference:
11/NW/0476). Written informed consent was obtained
from all patients recruited to the study.
QoL and AF symptom assessment
QoL and AF symptoms were assessed at baseline and
3 months after ablation using the SF-36 V2 and AFEQT
questionnaires. Questionnaires were completed without
input from study personnel. SF-36 V2 consists of 36
items that assess eight health domains: physical function-
ing, role limitations because of physical problems, bodily
pain, general health perception, vitality, social function-
ing, role limitations because of emotional problems and
mental health. In addition to these eight subscales, phys-
ical component summary (PCS) and mental component
summary (MCS) scores are also generated, which are
normalised to an overall population mean of 50±10.12
For all subscales, higher scores represent better func-
tioning and QoL. AFEQT is a 20-item questionnaire that
assesses four health domains: symptoms (n=4), daily
activities (n=8), treatment concern (n=6) and satisfac-
tion (n=2).13 It combines symptoms, functional status
and QoL in a single measure and its results have been
shown to be reproducible and responsive to change.13
Patients’ responses are scored using a seven-point Likert
scoring system and a linear relationship is observed
between global AFEQT scores and AF severity, with the
most severely affected patients having the lowest scores.
Ablation protocol
Pulmonary vein isolation
All patients underwent pulmonary vein isolation (PVI)
using one of three ablation technologies: (1) PVAC
multielectrode circumferential ablation catheter
(Medtronic Ablation Frontiers), (2) Arctic Front
Advance 28 mm cryoballoon (Medtronic CryoCath), and
(3) Wide-area circumferential ablation guided by the
CARTO 3 cardiac mapping system (Biosense Webster).
Electrical isolation of the pulmonary veins was confirmed
using standard pacing manoeuvres.
Left atrial substrate ablation
Additional complex fractionated atrial electrogram
(CFAE) and/or linear ablation was performed in patients
who remained in AF after PVI, according to the degree of
signal complexity and fractionation in the left atrium.
CFAE ablation
A detailed analysis of the left atrium and inter-atrial
septum was performed to identify CFAEs (focal sites
exhibiting constant electrical activity or multicomponent
electrograms with cycle length ≤120 ms averaged over a
10 s period), which were then ablated. This process was
completed when no residual CFAE sites could be identi-
fied or when sinus rhythm was restored by ablation.
Linear ablation
A combination of ‘roof line’ (connecting right and left
upper pulmonary vein ostia), ‘mitral line’ (connecting
left lower pulmonary vein ostium to mitral valve
annulus), and ‘inferior line’ (connecting right lower
pulmonary vein to coronary sinus) were constructed
depending on the degree of signal complexity in each
region. Linear ablation was performed until electro-
grams were no longer recordable or double potentials
were evident along the length of each line. Differential
pacing manoeuvres were not performed routinely to
further confirm conduction block. All patients in AF at
the end of the ablation procedure underwent electrical
cardioversion.
Clinical outcome
Clinical outcome was determined by symptom review,
12-lead ECG and 72 h Holter monitoring 3 months after
ablation and was divided into two categories: (1) ‘Sinus’
rhythm (no arrhythmia symptoms and no documented
AF episodes >30 s); (2) AF recurrence (arrhythmia symp-
toms and documented AF episodes >30 s).
Statistical analyses
Continuous variables are expressed as mean±SD. Patient
characteristics were compared between paroxysmal and
persistent AF groups using Student’s independent t test
for continuous variables and Pearson’s χ2 test for cat-
egorical variables.
Baseline QoL scores (AFEQT, PCS and MCS) were
compared and correlated with clinical parameters using
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Pearson’s correlation. Individual and summative health
domains of the AFEQT and SF-36 V2 questionnaires
were compared at baseline and 3 months after ablation
using Student’s paired t tests.
Change in QoL scores after ablation were correlated
with clinical parameters using Pearson’s correlation (con-
tinuous variables) and independent t test (categorical
variables) and were compared between different ablation
strategies using one-way analysis of variance (ANOVA).
Parameters with p<0.05 were entered into a multivariate
linear regression model using stepwise selection to assess
their independent and combined ability to predict
change in QoL after ablation. After multivariate analysis,
parameters with p<0.10 were retained. Standardised coef-
ficients (β) and corresponding p values are reported.
The magnitude of QoL change after ablation was com-
pared between AFEQT, PCS and MCS scores using
one-way ANOVA and correlation coefficients for the
three QoL scores and ablation outcome were compared
using Fisher r-to-z transformation. All tests were two-tailed
and p<0.05 was considered statistically significant.
RESULTS
The clinical characteristics of the 80 consecutive patients
recruited to the study are shown in table 1. The mean
age was 57±10 years and 73% were male. The mean dur-
ation of AF history was 4±3 years. Patients with persistent
AF (n=36) had a significantly shorter AF history, larger
left atrial volume and lower left ventricular ejection frac-
tion than those with paroxysmal AF (n=44). There were
no procedural complications and 54/80 (68%) patients
(77% paroxysmal; 56% persistent AF) maintained sinus
rhythm 3 months after ablation.
Effect of ablation on QoL
There was a significant increase in the summative and
individual health domain scores for both AFEQT (51.5
±22.0 vs 81.3±18.2; p<0.01) and SF-36 V2 (PCS 43.3±10.5
vs 47.9±11.3; p<0.01 and MCS 45.0±11.5 vs 51.5±9.4;
p<0.01) questionnaires in patients who maintained sinus
rhythm 3 months after ablation (figures 1A and 2A).
However, there was no significant change in summa-
tive or individual scores from either questionnaire in
patients with recurrent AF (figures 1B and 2B). The
magnitude of change in AFEQT score (25.4±19) after
ablation was significantly greater than the change in
PCS (6.8±6.4; p<0.01) or MCS (8.5±7.9; p<0.01) scores
and there was no significant difference observed
between the PCS and MCS scores (p=0.14). Change in
AFEQT score after ablation correlated more closely with
3-month outcome (r=0.55) than PCS (r=0.26; p=0.03) or
MCS (r=0.30; p=0.05) scores.
In univariate analysis, there was no significant correl-
ation between clinical parameters and change in QoL
scores after ablation (table 2). Of note, there was no dif-
ference in the magnitude of change in QoL after abla-
tion between paroxysmal and persistent AF groups
(AFEQT 24.3±24.3 vs 16.3±23.4, p=0.14; PCS 3.0±9.2 vs
3.1±8.7, p=0.98; MCS 5.8±11.2 vs 2.6±10.1, p=0.19).
However, higher QoL scores at baseline and AF recur-
rence correlated with smaller changes in QoL scores
after ablation for both questionnaires. In multivariate
analysis, higher AFEQT, PCS and MCS scores preabla-
tion and AF recurrence were independent predictors of
Table 1 Patient characteristics
Paroxysmal
AF (n=44)
Persistent
AF (n=36) p Value
Age (years) 56.9±10.5 58.2±9.5 0.58
Male gender 30 (68%) 28 (78%) 0.45
AF history
(years)
4.4±3.4 2.9±2.7 0.04
LA volume (mL) 53.1±17.2 64.6±20.1 <0.01
LVEF (%) 54.4±2.2 50.9±7.8 0.02
Hypertension 12 (27%) 14 (39%) 0.34
Diabetes 2 (5%) 5 (14%) 0.23
Smoking 22 (50%) 17 (47%) 0.83
AF, atrial fibrillation; LA, left atrial; LVEF, left ventricular ejection
fraction.
Figure 1 Mean individual and summative AFEQT scores
before and 3 months after ablation. (A) Patients who
maintained sinus rhythm post ablation; (B) Patients with
recurrent AF. AFEQT, Atrial Fibrillation Effect on
Quality-of-Life; DA, daily activities; SY, symptoms;
TC, treatment concern; TS, treatment satisfaction.
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a smaller change in their respective QoL scores after
ablation (table 3).
Change in QoL according to ablation strategy
AFEQT scores increased significantly after PVI, PVI
+Linear and PVI+Linear+CFAE ablation indicating an
improvement in QoL (table 4). AFEQT scores also
increased after PVI+CFAE ablation although this did not
meet statistical significance (p=0.12). There was a signifi-
cant increase in PCS and MCS scores after PVI and an
increase in MCS score after PVI+Linear ablation.
However, there was no significant change in PCS and
MCS scores after the other ablation strategies. Of note,
there was no significant difference in the magnitude of
change in QoL scores between the four ablation strat-
egies (AFEQT p=0.67; PCS p=0.49; MCS p=0.29).
Figure 2 Mean individual and summative SF-36 V2 scores
before and 3 months after ablation. (A) Patients who
maintained sinus rhythm post ablation; (B) Patients with
recurrent AF. PCS, physical component summary; MCS,
mental component summary; PF, physical functioning; RP,
role limitations because of physical problems; BP, bodily pain;
GH, general health perception; VT, vitality; SF, social
functioning; RE, role limitations because of emotional
problems; MH, mental health.
Table 2 Change in QoL scores after ablation: relationship with clinical parameters and ablation outcome
AFEQT
R/T (P)
PCS
R/T (P)
MCS
R/T (P)
Age −0.02 (0.87) 0.05 (0.70) −0.16 (0.15)
Female gender 0.28 (0.78) −1.14 (0.26) 1.31 (0.19)
Persistent AF 1.48 (0.14) −0.03 (0.98) 1.33 (0.19)
AF history −0.09 (0.44) −0.18 (0.11) −0.01 (0.96)
LA volume <−0.01 (0.98) 0.06 (0.63) −0.34 (<0.01)
LVEF 0.06 (0.61) −0.05 (0.68) 0.10 (0.38)
Hypertension −0.57 (0.57) −0.01 (0.99) −0.49 (0.63)
Diabetes 1.31 (0.20) 0.95 (0.34) −0.23 (0.82)
Smoking −1.96 (0.05) −0.40 (0.69) −0.67 (0.51)
Baseline
AFEQT −0.47 (<0.01) −0.10 (0.37) −0.13 (0.25)
PCS −0.22 (0.05) −0.34 (<0.01) 0.20 (0.08)
MCS −0.12 (0.30) 0.16 (0.17) −0.54 (<0.01)
Three-month outcome −5.79 (<0.01) −2.39 (0.02) −2.72 (<0.01)
AF, atrial fibrillation; AFEQT, Atrial Fibrillation Effect on Quality-of-Life; LA, left atrial; LVEF, left ventricular ejection fraction; MCS, mental
component summary; PCS, physical component summary.
R values from Pearson’s correlation (continuous variables) and T values from independent t tests (categorical variables) are shown.
Table 3 Multivariate predictors of change in QoL scores
after ablation
Parameter
Standardised
coefficient (β) p Value
AFEQT
AF recurrence 0.57 <0.01
Baseline AFEQT −0.56 <0.01
PCS
Baseline PCS −0.40 <0.01
Baseline MCS 0.25 0.02
AF recurrence 0.23 0.03
MCS
Baseline MCS −0.68 <0.01
AF recurrence 0.28 <0.01
Baseline PCS 0.27 <0.01
AF, atrial fibrillation; AFEQT, Atrial Fibrillation Effect on
Quality-of-Life; MCS, mental component summary; PCS, physical
component summary.
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Relationship between clinical variables and QoL
Baseline AFEQT scores correlated closely with PCS
scores (r=0.64, p<0.01) and moderately with MCS scores
(r=0.43, p<0.01). However, there was no correlation
between PCS and MCS scores (r=0.16, p=0.15).
Hypertension was associated with a lower baseline
AFEQT score with a trend towards a lower MCS score
(table 5). Older age and persistent AF were associated
with a lower PCS score. Diabetes was associated with a
lower MCS score with a trend towards a lower PCS score.
Larger left atrial volume was associated with a higher
MCS score, which is unlikely to be clinically meaningful.
DISCUSSION
Effect of ablation on QoL
The main finding of this prospective study is the signifi-
cant improvement in AF symptoms and QoL in patients
who maintained sinus rhythm 3 months after ablation and
the contrasting lack of improvement in patients with recur-
rent AF. This finding was consistent across all individual
and summative components of the AFEQT and SF-36 V2
questionnaires. The mean increase in AFEQT score of 30
points in patients who maintained sinus rhythm is consist-
ent with a marked improvement in QoL.14 The expected
lack of QoL improvement in patients with recurrent AF
after ablation is clinically coherent and supported by Fiala
et al15 and Mohanty et al.16 However, other groups have
reported significant QoL improvements regardless of
arrhythmia outcome.9–11 This might be explained by a
transition from symptomatic to asymptomatic AF, reduc-
tion in AF burden short of AF abolition or placebo effect.
Previous studies have shown that AF specific QoL
scales are more responsive to QoL change in this popu-
lation and correlate better with ablation outcome.9 13
This is corroborated by the greater change in QoL score
after ablation and the stronger correlation with ablation
outcome observed with the AFEQT questionnaire in this
study. There was no significant correlation between the
clinical parameters examined (including AF type) and
change in QoL scores after ablation, as shown by
others.9–11
However, Bulkova et al17 reported that long-standing
persistent AF, younger age and a shorter history of AF
were associated with an improvement in QoL 3 years
after ablation. The different patient populations and
longer duration of follow-up could explain the discord-
ance in results. In agreement with others, higher QoL
scores pre-ablation and AF recurrence were independent
predictors of a smaller change in the respective QoL
score after ablation.9 11 14 This suggests a ceiling effect,
as there is less potential for improvement after ablation
in those with preserved QoL beforehand.
Change in QoL according to ablation strategy
Mantovan et al11 reported a significant improvement in
PCS and MCS scores after PVI, CFAE and PVI+CFAE
ablation strategies with the exception of MCS in the
CFAE ablation group. In our study, we observed a signifi-
cant increase in all three QoL scores after PVI; however,
there was no significant improvement in PCS and MCS
scores after PVI+CFAE ablation. This is likely a chance
effect on account of the small number of patients in this
subgroup. To our knowledge, the effect of PVI+Linear
ablation on QoL has not been previously reported. In
this study, PVI+Linear ablation was associated with a sig-
nificant improvement in AFEQT and MCS scores;
however, there was no significant difference in PCS
scores. Of note, there was no significant difference in
the magnitude of QoL change after ablation between
the four ablation strategies.
Table 4 Change in QoL scores according to ablation strategy
AFEQT PCS MCS
Baseline 3 months p Value Baseline 3 months p Value Baseline 3 months p Value
PVI (n=45) 53.4±22.3 76.7±20.9 <0.01 43.8±10.7 47.0±11.0 0.02 44.3±12.1 49.8±9.1 <0.01
PVI+Linear (n=17) 47.6±23.0 62.7±25.5 0.04 44.5±9.8 44.9±10.4 0.82 45.4±10.5 50.9±9.4 0.04
PVI+CFAE (n=8) 39.2±15.3 56.9±22.3 0.12 38.2±12.5 43.2±11.7 0.26 44.1±13.8 47.0±11.6 0.46
PVI+Linear+CFAE (n=10) 52.1±23.2 72.5±29.0 0.02 43.0±13.0 48.2±15.8 0.14 49.5±8.3 48.0±14.1 0.65
CFAE, complex fractionated atrial electrogram; MCS, mental component summary; PCS, physical component summary; PVI, pulmonary vein
isolation; QoL, quality of life.
Table 5 Baseline QoL scores and clinical parameters
AFEQT
R/T (P)
PCS
R/T (P)
MCS
R/T (P)
Age −0.14 (0.22) −0.35 (<0.01) 0.05 (0.69)
Female
gender
1.01 (0.31) 1.13 (0.26) −0.14 (0.89)
Persistent
AF
1.64 (0.10) 2.05 (0.04) 0 (1)
AF history 0.14 (0.22) 0.20 (0.09) −0.04 (0.76)
LA volume −0.03 (0.82) −0.20 (0.09) 0.33 (<0.01)
LVEF −0.01 (0.96) 0.12 (0.29) −0.08 (0.47)
Hypertension 2.22 (0.03) 1.43 (0.16) 1.93 (0.06)
Diabetes 1.38 (0.17) 1.81 (0.07) 2.64 (0.01)
Smoking 1.21 (0.23) 0.35 (0.73) 0.96 (0.34)
R values from Pearson’s correlation (continuous variables) and T
values from independent t tests (categorical variables) are shown.
AFEQT, Atrial Fibrillation Effect on Quality-of-Life; AF, atrial
fibrillation; CFAE, complex fractionated atrial electrogram; LA, left
atrial; LVEF, left ventricular ejection fraction; MCS, mental
component summary; PCS, physical component summary; PVI,
pulmonary vein isolation; QoL, quality of life.
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Relationship between clinical variables and QoL
This study showed no correlation between gender and
QoL, in contrast to Reynolds et al18 who reported that
female patients were more symptomatic from AF with a
consequent reduction in QoL. In addition, they
reported that older patients (>65 years) had fewer AF
symptoms than their younger counterparts, which was
not observed in this study. The disparity in results may
be explained by different patient populations and eras
of AF management as they studied patients with new-
onset AF who were managed pharmacologically prior to
the development of AF ablation; whereas, we studied
patients referred for ablation who, by their very nature,
have a high AF symptom burden and reduced QoL.
Hypertension was associated with a higher symptom
burden and reduced QoL secondary to AF in this study,
which has not been previously reported. Persistent AF
was associated with lower physical health scores than par-
oxysmal AF, as shown by Bulkova et al.17 However, there
was no difference in AF symptom burden between the
two groups, which contradicts the common belief that
symptoms regress as AF progresses from paroxysmal to
persistent forms. Finally, diabetes was associated with
lower mental health and a trend towards lower physical
health scores in this study, which supports its negative
impact on QoL.
Limitations
First, the choice of ablation strategy after PVI was not
randomised and was dependent on the operator and the
degree of signal complexity in the left atrium. Second,
this was a prospective cohort study without a randomised
control group comparing AF ablation to best non-
ablative management (rate vs rhythm control). However,
the superiority of ablation over antiarrhythmic drugs in
improving QoL has been demonstrated consistently.
Third, AF recurrence was determined by patients’ symp-
toms, 12-lead ECG and 72 h Holter monitoring
3 months after ablation and not by continuous ECG
monitoring. Although, we cannot completely exclude
asymptomatic AF episodes in the ‘sinus rhythm’ group,
we consider this unlikely given previous AF symptoms.
Fourth, change in QoL was assessed 3 months after abla-
tion in line with the first outpatient clinic review and
therefore, the longer-term effect of ablation on QoL is
unknown. Finally, patients enrolled in this study had
been referred for catheter ablation and therefore, repre-
sent a select cohort with a high AF symptom burden.
Extrapolation of the benefits demonstrated to a wider
population requires caution.
Conclusions
Patients who maintained sinus rhythm after ablation had
a significant improvement in AF symptoms and QoL. No
improvement was observed in patients with recurrent AF.
QoL did not correlate with either baseline clinical para-
meters or extent of ablation.
AF specific QoL scales are more responsive to change
than generic measures and correlate better with arrhyth-
mia outcome.
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